← Back to headlines
Replimune stock surges after FDA advisers back skin cancer drug
Shares of Replimune surged significantly after FDA advisers provided a positive recommendation for the company's skin cancer drug.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Jane Street Suffers $15 Billion Loss in July Due to Market Ructions
39m ago
Selena Gomez Sued for Alleged Fraud in Mental Health Startup
40m ago
Nvidia Discloses $21 Billion Stake in SpaceX and $30 Billion in Intel
1h ago
Consortium Seals $1.9 Billion Investment in Liverpool FC, Amit Bhatia Named Vice-Chairman
1h ago